Answers are grounded in this paper and cite their sources.
Scleroderma bovista fermentation broth (SBF) exhibits anti-inflammatory activity, but its effect on ulcerative colitis (UC) remains unclear. LC-MS/MS analysis revealed that SBF contains 43 compounds, including sclerocitrin homologs, cyclic peptides, and alkaloids. In vitro, SBF (20–40 μg/mL) promoted cell viability in LPS-stimulated RAW264.7 macrophages, suppressed nitric oxide overproduction, reduced iNOS, IL-1β, and COX-2 expression, and upregulated IL-10 mRNA expression. In vivo, in a dextran sulfate sodium (DSS)-induced colitis model, SBF (50–200 mg/kg) dose-dependently mitigated DSS-induced weight loss, disease activity, splenomegaly, colon shortening, crypt damage, and representative images suggested a reduction in macrophage infiltration. The highest dose (SBF200) showed efficacy comparable to that of 5-ASA. Mechanistically, SBF reduced colonic IL-1β, TNF-α, and IL-6 levels and inhibited NF-κB activation by decreasing phosphorylated IκBα and p65. Colonic IL-10, which was elevated in DSS-treated mice, was lower in SBF groups than in the 5-ASA group. Furthermore, 16S rRNA sequencing showed that SBF lowered the DSS-elevated Shannon index and shifted the PCoA profiles of colitic mice toward the control group. At the genus level, SBF treatment further enriched Akkermansia (already elevated in DSS mice compared with controls) and increased Faecalibaculum, while reducing the relative abundance of Turicibacter, Clostridium, and Enterococcus; Ligilactobacillus was only partially restored and remained below control levels. Thus, SBF prophylactically mitigates DSS-induced colitis by suppressing inflammation, inhibiting NF-κB signaling, and modulating the gut microbiota, supporting further investigation of SBF as a potential fungal-derived candidate for UC treatment.
No takes yet. Share an insight, caveat, or question.
Ying et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: